Venous Access Device Manufacturing in European Union 2026: Industry Statistics & Trends

The venous access device manufacturing industry in the European Union involves the production of specialized medical equipment like central venous catheters, peripherally inserted central catheters (PICCs), and peripheral IV lines utilized for administering medications and fluids directly into the bloodstream. The sector operates as a crucial component of the broader European medical technology framework, which employed over 760,000 people and comprised more than 33,000 companies across Europe as of 2021 (MedTech Europe). Driven by an aging population and a high prevalence of chronic illnesses requiring long-term clinical care, the industry continues to pivot toward advanced material coating

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Venous Access Device Manufacturing in European Union industry cover?

The venous access device manufacturing industry comprises the engineering, fabrication, and assembly of clinical hardware designed to establish direct entry into the human circulatory system. These products include short peripheral intravenous catheters (PIVCs), midline catheters, peripherally inserted central catheters (PICCs), central venous catheters (CVCs), and implantable subcutaneous ports. The core manufacturing processes demand strict cleanroom environments, medical-grade polymers, advanced extrusion technologies, and biocompatible surface coatings.

• •Covers vascular access devices categorised under the production of medical and surgical instruments.
• •Includes the integration of automated safety mechanisms to minimize needle-stick injury risks for healthcare professionals.
• •Products are classified based on patient dwell-time, spanning from short-term acute care devices to long-term chronic treatment components.

Who operates in the industry and how is it structured?

The organizational landscape of medical device manufacturing across the EU is highly dominated by small and medium-sized enterprises (SMEs) operating alongside major global multi-nationals. Official regional tracking highlights a dense concentration of manufacturing clusters located within specific member states, notably Germany, France, Italy, and Ireland. These entities feed a regional market that represents one of the largest medical technology landscapes globally.

• •According to official figures from MedTech Europe, small and medium-sized enterprises make up approximately 95% of the medical technology corporate structure.
• •Germany maintains the highest absolute volume of industrial employment in the overarching medical technology sector.
• •Ireland and Switzerland exhibit the highest concentration of medical device sector employees per capita within the European continent.

What drives demand in the industry?

The consumption of venous access apparatus is inextricably linked to changing demographic profiles and evolving clinical care models within Europe. An accelerating geriatric population naturally increases the regional clinical burden of chronic cardiovascular conditions, oncological diseases, and renal failures that mandate prolonged vascular therapies. Furthermore, public health efforts prioritize institutional safety frameworks, which consistently mandate the phase-out of legacy, non-safety-engineered intravenous lines.

• •Eurostat demographic projections indicate that the proportion of individuals aged 80 or above in the EU population will expand 2.5-fold between 2024 and 2100, growing from 6.1% to 15.3%.
• •European Patent Office (EPO) data indicates that medical technology accounted for 15,900 patent applications in 2023, reflecting high continuous technical evolution.
• •An expanding shift toward ambulatory surgical centers (ASCs) and home healthcare models escalates demand for secure, long-dwell PICC lines and midlines.

Who are the notable companies in the industry?

The European theater features fierce competition between massive international conglomerates and specialized regional medical components producers. These entities utilize extensive distribution networks to supply public health systems and private hospital purchasing groups across EU member states. Key players focus heavily on product differentiation via antimicrobial coatings and proprietary navigation technologies for catheter placement.

• •B. Braun Melsungen AG, headquartered in Germany, is a major manufacturer of infusion therapy and vascular access solutions.
• •Becton, Dickinson and Company (BD) maintains substantial production facilities and operational infrastructure across multiple EU member states.
• •Vygon SA, an established medical device manufacturer based in France, specializes in high-quality vascular access and neonatological catheters.
• •Teleflex Incorporated supplies central venous and specialized vascular access products extensively throughout Europe via regional subsidiaries.

What are the recent trends and outlook?

Industrial development is characterized by significant shifts toward advanced material sciences to mitigate catheter-associated complications like thrombosis and localized infections. Manufacturers are heavily investing in anti-thrombogenic materials and silver-ion or chlorhexidine-impregnated polymers. Concurrently, geopolitical supply chain revisions are pushing firms to secure domestic, European-based cleanroom compounding and precision molding operations.

• •Growing adoption of tip-location and navigation software to optimize central venous catheter tip placement at the bedside.
• •Rising clinical transition from standard peripheral IVs toward midline catheters for intermediate therapies lasting up to 29 days.
• •Increased focus on sustainable, eco-friendly sterilization methodologies as alternatives to traditional ethylene oxide processing.

How is the industry regulated?

Compliance within the EU is governed by rigorous legislative frameworks that manage the life cycle of every manufactured device from design to post-market surveillance. The transition to updated centralized regulations has significantly intensified the clinical data requirements and technical oversight demanded from producers. Manufacturers must coordinate directly with independent notified bodies to achieve validation before distributing goods inside the single market.

• •All venous access devices manufactured or sold in the single market are strictly regulated under the European Medical Devices Regulation, specifically Regulation (EU) 2017/745 (MDR).
• •The MDR fully replaced legacy directives 93/42/EEC and 90/385/EEC, enforcing heightened rules for clinical evaluations and post-market tracking.
• •Products are assigned precise risk classifications (such as Class IIa, IIb, or Class III for long-term central implants) which dictate the exact level of oversight mandatory from designated Notified Bodies.

Government, statistical and trade sources used for this Claight analysis.

• MedTech Europe The European Medical Technology Industry in figures 2021 ·
• Eurostat Industrial Production Statistics (DS-059358) ·
• European Patent Office (EPO) Annual Statistics 2023 ·
• European Parliament and Council Regulation (EU) 2017/745